Abstract CT271: PRECISION (Profiling early breast cancer for radiotherapy omission): A phase II study of breast-conserving surgery without adjuvant radiotherapy for favorable-risk breast cancer
Mira Patel(Memorial Sloan Kettering Cancer Center), Lior Z. Braunstein(Memorial Sloan Kettering Cancer Center), Giulia DiGiovanni(Dana-Farber Cancer Institute), David E. Wazer(Brown University), Rachel Jimenez(Mass General Brigham), Deborah Dillon(Harvard University), Paul J. Catalano(Computational Physics (United States)), Eric P. Winer(University of Vermont), Yu‐Hui Chen(Dana-Farber Cancer Institute), Carmen A. Perez, Jennifer R. Bellon(Brigham and Women's Hospital), Julia S. Wong(Brigham and Women's Hospital), Jean L. Wright(University of North Carolina at Chapel Hill)
Cited by 5
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k